NASDAQ · DARE
Healthcare · Biotechnology
$0.66
Up+$0.01 (+1.83%)
Updated Nov 5, 2026, 2:37 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DARE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
DARE closed at $0.66 after 21 trading sessions, down 16.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.66 | $0.69 | $0.63 | $0.6619 | 228.39K |
| Nov 3, 2026 | $0.6533 | $0.66 | $0.6201 | $0.65 | 138.94K |
| Nov 2, 2026 | $0.739 | $0.739 | $0.646 | $0.655 | 206.41K |
| Oct 30, 2026 | $0.7026 | $0.7026 | $0.67 | $0.6996 | 654.01K |
| Oct 29, 2026 | $0.67 | $0.6975 | $0.6638 | $0.6815 | 46.86K |
| Oct 28, 2026 | $0.6799 | $0.68 | $0.6632 | $0.68 | 46.14K |
| Oct 27, 2026 | $0.6431 | $0.6839 | $0.6431 | $0.663 | 52.09K |
| Oct 26, 2026 | $0.6681 | $0.675 | $0.6401 | $0.6438 | 50.55K |
| Oct 23, 2026 | $0.64 | $0.6659 | $0.6382 | $0.6459 | 56.54K |
| Oct 22, 2026 | $0.6851 | $0.7131 | $0.625 | $0.6517 | 327.9K |
| Oct 21, 2026 | $0.68 | $0.7118 | $0.6734 | $0.688 | 24.81K |
| Oct 20, 2026 | $0.7231 | $0.7297 | $0.67 | $0.689 | 217.69K |
| Oct 19, 2026 | $0.7273 | $0.7381 | $0.68 | $0.706 | 251.99K |
| Oct 16, 2026 | $0.7392 | $0.7397 | $0.7126 | $0.7246 | 77.21K |
| Oct 15, 2026 | $0.73 | $0.7462 | $0.7204 | $0.74 | 96.95K |
| Oct 14, 2026 | $0.7426 | $0.7426 | $0.7203 | $0.729 | 61.04K |
| Oct 13, 2026 | $0.786 | $0.786 | $0.73 | $0.7477 | 116.07K |
| Oct 12, 2026 | $0.77 | $0.7901 | $0.7381 | $0.7501 | 81.98K |
| Oct 9, 2026 | $0.79 | $0.7904 | $0.7601 | $0.7734 | 70.04K |
| Oct 8, 2026 | $0.7862 | $0.80 | $0.755 | $0.7722 | 170.79K |
| Oct 7, 2026 | $0.8143 | $0.8194 | $0.79 | $0.79 | 113.41K |
The latest Smart Investors Daily articles mentioning DARE.
Company
Market Activity
Research & News
DARE research
Company profile and research snapshot.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 2, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 4, 2025 | Maxim Group | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 17, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 30, 2026
With this installment, Daré Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The remaining approximately $5.6 million of the up to approximately $48.9
Yahoo · Oct 28, 2026
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience’s growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs in women’s health Access the segment here SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world so
Yahoo · Oct 26, 2026
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Liz Proos, Vice
Yahoo · Oct 19, 2026
Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer The program addresses non-hormonal approaches to women’s sexual health which aligns with Daré Bioscience's innovation strategy and development of proprietary Sildenafil Cream, 3.6% Daré Bioscience will also present research on Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Soc
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DARE.
